Human Reproduction, Vol 13, 793-798, Copyright © 1998 by Oxford University Press
HB Croxatto, L Kovacs, R Massai, BA Resch, B Fuentealba, AM Salvatierra, HD Croxatto, S Zalanyi, S Viski and L Krenacs
Low-dose antiprogestin administration has been proposed as a new
contraceptive modality to interference with endometrial receptivity without
disturbing ovarian function. The effects of 1 mg/day mifepristone for 150
days on the menstrual cycle were assessed in 21 surgically sterilized
women. The aim was to study each woman for one control cycle and during
months 1, 3 and 5 of treatment. Ovulation, endometrial thickness, serum
oestradiol and progesterone, urinary luteinizing hormone, endometrial
morphology and cervical mucus were assessed. Luteal phase progesterone
concentrations were observed in 36 of the 60 treated months assessed and
less frequently as treatment progressed. The bleeding pattern was regular
in most biphasic cycles, while prolonged interbleeding intervals or no
bleeding were associated with monophasic cycles. Altered endometrial
morphology was found in all cases irrespective of the occurrence of luteal
activity. Increased endometrial thickness and dilated glands were observed
in 25 and 34% respectively of the monophasic cycles. Mifepristone, 1
mg/day, interferes with endometrial development while allowing the
occurrence of biphasic ovarian cycles and regular bleeding. However, it
also prevents ovarian cyclicity in a high proportion of treated months, and
this is associated with increased endometrial growth in some women, which
may be of concern.
REVIEWS
Effects of long-term low-dose mifepristone on reproductive function in women
Instituto Chileno de Medicina Reproductiva, Santiago, Chile.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  F. M. Horne and D. L. Blithe Progesterone receptor modulators and the endometrium: changes and consequences Hum. Reprod. Update, November 1, 2007; 13(6): 567 - 580. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. K. Jain, A. Li, W. Yang, P. Minoo, and J. C. Felix Effects of mifepristone on proliferation and apoptosis of human endometrium in new users of medroxyprogesterone acetate Hum. Reprod., March 1, 2006; 21(3): 798 - 809. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Chabbert-Buffet, G. Meduri, P. Bouchard, and I. M. Spitz Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications Hum. Reprod. Update, May 1, 2005; 11(3): 293 - 307. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Chwalisz, W. Elger, T. Stickler, C. Mattia-Goldberg, and L. Larsen The effects of 1-month administration of asoprisnil (J867), a selective progesterone receptor modulator, in healthy premenopausal women Hum. Reprod., April 1, 2005; 20(4): 1090 - 1099. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Narvekar, S. Cameron, H. O. D. Critchley, S. Lin, L. Cheng, and D. T. Baird Low-Dose Mifepristone Inhibits Endometrial Proliferation and Up-Regulates Androgen Receptor J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2491 - 2497. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D.T. Baird, A. Brown, H.O.D. Critchley, A.R. Williams, S. Lin, and L. Cheng Effect of long-term treatment with low-dose mifepristone on the endometrium Hum. Reprod., January 1, 2003; 18(1): 61 - 68. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Brown, L. Cheng, S. Lin, and D. T. Baird Daily Low-Dose Mifepristone Has Contraceptive Potential by Suppressing Ovulation and Menstruation: A Double-Blind Randomized Control Trial of 2 and 5 mg per Day for 120 Days J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 63 - 70. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Marions, S. Viski, K. G. Danielsson, B. A. Resch, M.-L. Swahn, M. Bygdeman, and L. Kovacs Contraceptive efficacy of daily administration of 0.5 mg mifepristone Hum. Reprod., November 1, 1999; 14(11): 2788 - 2790. [Abstract] [Full Text] [PDF]
|
|